口服抗生素与严重皮肤药物不良反应风险
该巢式病例对照研究利用加拿大安大略省2002至2022年人口学链接行政数据,纳入66岁及以上、至少接受1种口服抗生素的成人。严重皮肤药物不良反应病例定义为处方后60天内因此就诊急诊或住院者,每例匹配至多4例对照。共识别21 758例病例(中位年龄75岁,64.1%女性)和87 025例匹配对照。以大环内酯类为参照,磺胺类(aOR 2.9;95%CI 2.7-3.1)与头孢菌素类(aOR 2.6;95%CI 2.5-2.8)关联最强,呋喃妥因、青霉素类、氟喹诺酮类亦有关联;作者建议临床合适时优先选用低风险抗生素。
要点
- 以口服大环内酯类为参照,磺胺类抗生素与严重皮肤药物不良反应的关联最强(aOR 2.9;95%CI 2.7-3.1),头孢菌素类次之(aOR 2.6;95%CI 2.5-2.8)。
- 与严重皮肤药物不良反应还可见关联的包括呋喃妥因(aOR 2.2;95%CI 2.1-2.4)、青霉素类(aOR 1.4;95%CI 1.3-1.5)、氟喹诺酮类(aOR 1.3;95%CI 1.2-1.4)。
- 因皮肤药物不良反应急诊就诊或住院的粗发生率以头孢菌素类最高(4.92/1000张处方;95%CI 4.86-4.99),磺胺类次之(3.22/1000张处方;95%CI 3.15-3.28)。
- 2852例因皮肤药物不良反应住院的病例中,中位住院时间6天(IQR 3-13天),9.6%需转入重症监护病房,5.3%院内死亡。
- 作者认为,临床合适时应优先选用低风险抗生素。
适用人群与场景
- 2002至2022年加拿大安大略省66岁及以上、接受至少1种口服抗生素的成人。
- 病例为处方后60天内因严重皮肤药物不良反应就诊急诊或住院者,每例匹配至多4例未发生该结局的对照。
诊断标准与关键阈值
- 严重皮肤药物不良反应定义为涉及皮肤和内脏器官、可能危及生命的药物超敏反应。
- 病例定义:口服抗生素处方后60天内因严重皮肤药物不良反应就诊急诊或住院。
红旗征与不能漏的情况
- 严重皮肤药物不良反应可累及皮肤和内脏器官、可能危及生命;住院病例中9.6%需转入重症监护病房、5.3%院内死亡。
研究设计与关键结果
- 研究类型:基于人群链接行政数据的巢式病例对照研究;人群:加拿大安大略省66岁及以上口服抗生素成人;暴露:不同类别口服抗生素,以大环内酯类为参照;主要终点:严重皮肤药物不良反应。
- 共识别21 758例病例(中位年龄75岁;64.1%女性)和87 025例匹配对照。
- 磺胺类抗生素aOR 2.9(95%CI 2.7-3.1)、头孢菌素类aOR 2.6(95%CI 2.5-2.8),与大环内酯类相比关联最强。
- 呋喃妥因aOR 2.2(95%CI 2.1-2.4)、青霉素类aOR 1.4(95%CI 1.3-1.5)、氟喹诺酮类aOR 1.3(95%CI 1.2-1.4)。
- 因皮肤药物不良反应急诊就诊或住院的粗发生率:头孢菌素类4.92/1000张处方(95%CI 4.86-4.99),磺胺类3.22/1000张处方(95%CI 3.15-3.28)。
- 2852例因皮肤药物不良反应住院的病例中,中位住院时间6天(IQR 3-13天),9.6%需转入重症监护病房,5.3%院内死亡。
证据类型、等级与局限
- 证据类型:基于人群链接行政数据的巢式病例对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者建议,临床合适时应优先选用低风险抗生素;与大环内酯类相比,磺胺类和头孢菌素类与严重皮肤药物不良反应的关联最强。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Serious cutaneous adverse drug reactions (cADRs) are potentially life-threatening drug hypersensitivity reactions involving the skin and internal organs. Antibiotics are a recognized cause of these reactions, but no studies have compared relative risks across antibiotic classes.
OBJECTIVES: To explore the risk of serious cADRs associated with commonly prescribed oral antibiotics, and to characterize outcomes of patients hospitalized for them.
DESIGN, SETTING, AND PARTICIPANTS: Nested case-control study using population-based linked administrative datasets among adults aged 66 years or older who received at least 1 oral antibiotic between 2002 and 2022 in Ontario, Canada. Cases were those who had an emergency department (ED) visit or hospitalization for serious cADRs within 60 days of the prescription, and each case was matched with up to 4 controls who did not.
EXPOSURE: Various classes of oral antibiotics.
MAIN OUTCOMES AND MEASURES: Conditional logistic regression estimate of the association between different classes of oral antibiotics and serious cADRs, using macrolides as the reference group.
RESULTS: During the 20-year study period, we identified 21 758 older adults (median age, 75 years; 64.1% female) who had an ED visit or hospitalization for serious cADRs following antibiotic therapy and 87 025 matched controls who did not. In the primary analysis, sulfonamide antibiotics (adjusted odds ratio [aOR], 2.9; 95% CI, 2.7-3.1) and cephalosporins (aOR, 2.6; 95% CI, 2.5-2.8) were most strongly associated with serious cADRs relative to macrolides. Additional associations were evident with nitrofurantoin (aOR, 2.2; 95% CI, 2.1-2.4), penicillins (aOR, 1.4; 95% CI, 1.3-1.5), and fluoroquinolones (aOR, 1.3; 95% CI, 1.2-1.4). The crude rate of ED visits or hospitalization for cADRs was highest for cephalosporins (4.92 per 1000 prescriptions; 95% CI, 4.86-4.99) and sulfonamide antibiotics (3.22 per 1000 prescriptions; 95% CI, 3.15-3.28). Among the 2852 case patients hospitalized for cADRs, the median length of stay was 6 days (IQR, 3-13 days), 9.6% required transfer to a critical care unit, and 5.3% died in the hospital.
CONCLUSION AND RELEVANCE: Commonly prescribed oral antibiotics are associated with an increased risk of serious cADRs compared with macrolides, with sulfonamides and cephalosporins carrying the highest risk. Prescribers should preferentially use lower-risk antibiotics when clinically appropriate.
参考来源
- Lee EY, Gomes T, Drucker AM, et al. Oral Antibiotics and Risk of Serious Cutaneous Adverse Drug Reactions. JAMA. 2024. PMID: 39115856. doi:10.1001/jama.2024.11437
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。